FMED
Fidelity Disruptive Medicine ETF
FMED is an actively managed fund that invests in companies from around the world involved in disruptive innovation in Health Care.
Global
EQUITY
Active
MANAGEMENT STYLE
$ 56.2 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | Apr 16, 2020 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| DANAHER CORP | 3.7 % |
| INTUITIVE SURGICAL INC | 3.6 % |
| COGENT BIOSCIENCES INC | 3.4 % |
| UCB SA | 3.4 % |
| ALNYLAM PHARMACEUTICALS INC | 3.1 % |
| LIFESTANCE HEALTH GROUP, INC. | 3.0 % |
| ARGENX SE ADR | 2.8 % |
| BIO-TECHNE CORPORATION | 2.7 % |
| INSMED INC | 2.5 % |
| UNITEDHEALTH GROUP INC | 2.5 % |
Constituent Breakdown
| Number of holdings | 74 |
| Herfindahl-Hirschman Index | 198 |
| Wgt avg mkt cap (mns) | $60,176 |
| Large cap (>$10bn) | 54.1% |
| Mid cap ($2-10bn) | 24.3% |
| Small cap (<$2bn) | 11.7% |
| Developed mkts. | 93.3% |
| Emerging mkts. | 0.7% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 82.5 % |
 |
BELGIUM | 3.4 % |
 |
NETHERLANDS | 2.8 % |
 |
FRANCE | 1.9 % |
 |
DENMARK | 1.5 % |
 |
SWITZERLAND | 1.3 % |
 |
CHINA | 0.9 % |
 |
BRITAIN | 0.9 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -8.3% | 3.7% | 1.9% | -- | -- | -- | -- | -0.7% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | -- | -- | -- | -- | 0.0% |
| Total Returns | -8.3% | 3.7% | 1.9% | -- | -- | -- | -- | -0.7% | Ann. Volatility | 21.8% | 19.0% | 19.2% | -- | -- | -- | -- | 18.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.97 | 40% |
| MSCI EAFE | 0.80 | 37% |
| MSCI Emg Mkts | 0.54 | 28% |
Liquidity Measures
| Avg. volume (000) | 34 |
| ADV traded (mns) | $1 |
| Turnover | 1.5% |
| Avg. Bid/Ask (% of price) | 0.24% |
Technical Indicators
| 30d moving avg. (EMA) | $24.94 |
| Relative strength (RSI) | 42 |
| MACD/Signal | -0.17/-0.09 |
| Bollinger Bands (Upper/Lower) | $26.03/$23.95 |
| Short interest (% of AUM) | 0.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. FMED |
Expenses vs. FMED |
ALTAR Score™ vs. FMED |
|---|---|---|---|---|
| MEDI | Harbor Health Care ETF | 28.4% | +30 bp | +0.4% |
| BMED | Future Health ETF | 25.1% | +35 bp | +2.3% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 24.9% | +25 bp | +2.8% |
| HRTS | Tema Heart & Health ETF | 22.2% | +25 bp | +4.7% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 21.7% | +18 bp | +3.8% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 20.7% | +15 bp | +2.6% |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 19.5% | -10 bp | +8.6% |
| FHLC | Fidelity MSCI Health Care Index ETF | 18.6% | -42 bp | +7.3% |
| XBI | State Street SPDR S&P Biotech ETF | 18.3% | -15 bp | +1.2% |
| VHT | Vanguard Health Care ETF | 18.0% | -41 bp | +7.1% |
Risk and Returns: FMED vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/17/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.3%
ALTAR SCORE™
2nd
PERCENTILE
AVOID
ETFRC RATING
There are 584 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. FMED's ALTAR Score™ is approximately -2.1 standard
deviations above the category average. This places FMED in the 2nd percentile
among funds in the category.
Sell-Side Consensus
$32.93
PRICE TARGET
+36.9%
UPSIDE